I like your posts on OCC, they're informative and accurate. Except when you bring up that STI called MSB (Give it up, MSB is worthless trash).
The future is bright for OCC. That is, if they move their focus to the US. Australia is a waste land for biotechs, STEM and regenerative medicine.
OCC should leverage its proven success and expertise in obtaining US and EU regulatory approvals by listing its stock the US where its IP will be properly valued and recognized. Not a dual listing with ADRs.
Delist entirely from the ASX and relist on NASDAQ with roadshow and proper marketing of the science and tech to VC and investors able to move markets.
Many US biotechs with no regulatory approvals or distribution deals are valued 100x OCC, because the US/Global market is hungry for biotech.
OCC Trading, page-1307
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.5¢ | $49.66K | 129.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20305 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 77938 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |